VIDEO: Avoidable Costs in U.S. Healthcare

Article

Doug Long, VP, Industry Relations, IMS Health, discusses the report: "Avoidable Costs in U.S. Healthcare: The $200 Billion Opportunity from Using Medicines More Responsibly."

Doug Long, VP, Industry Relations, IMS Health, discusses the report: "Avoidable Costs in U.S. Healthcare: The $200 Billion Opportunity from Using Medicines More Responsibly."

Recent Videos
Related Content
Inhaled Insulin for Pediatric Patients Shows Positive Results in Phase 3 Trial

Inhaled Insulin for Pediatric Patients Shows Positive Results in Phase 3 Trial

Killian Meara
December 18th 2024
Article

MannKind announced results from the INHALE-1 study that examined Afrezza in children and adolescents with diabetes.

Over the Counter, the podcast from Drug Topics

Episode 6: High Risk: Diabetes and COVID-19

Drug Topics staff
July 24th 2020
Podcast

In this episode of Over the Counter, 2 experts on diabetes management and care discuss the effect COVID-19 is having on individuals with diabetes and the ways that the health care system is responding.

Examining Impact of Continuous Glucose Monitors on Diabetes | ASHP Midyear

Examining Impact of Continuous Glucose Monitors on Diabetes | ASHP Midyear

Killian Meara
December 16th 2024
Article

Two posters presented at the meeting looked into the topic CGMs in diabetes care.

Q&A: Pharmacists’ Understanding of CKD Therapies, Adverse Effects | ASHP Midyear

Q&A: Pharmacists’ Understanding of CKD Therapies, Adverse Effects | ASHP Midyear

Brian Nowosielski;Denise Kelley, PharmD, BCPS, FASHP ;Ashley Gallagher
December 13th 2024
Article

Denise Kelley, PharmD, BCPS, FASHP, joined Drug Topics to discuss various medications for chronic kidney disease and their common adverse reactions.

SGLT2 Inhibitors May Have Clinical Benefits For Patients with Diabetes After Myocardial Infarction | ASHP Midyear

SGLT2 Inhibitors May Have Clinical Benefits For Patients with Diabetes After Myocardial Infarction | ASHP Midyear

Killian Meara
December 11th 2024
Article

Research found that SGLT2 inhibitors were associated with a lower risk of major cardiovascular events or hospitalization for heart failure.

Assessing Improvements to Reduce Insulin-Related Hypoglycemic Events | ASHP Midyear

Assessing Improvements to Reduce Insulin-Related Hypoglycemic Events | ASHP Midyear

Killian Meara
December 10th 2024
Article

Medication alerts, nurse education, and pharmacist interventions led to lower hypoglycemic events every year after they were implemented.

© 2024 MJH Life Sciences

All rights reserved.